Stockscreener 앱 받기
0.66
3.45%
-0.0236
전일 마감가:
$0.6836
열려 있는:
$0.69
하루 거래량:
2.42M
Relative Volume:
0.52
시가총액:
$142.89M
수익:
-
순이익/손실:
$-111.13M
주가수익비율:
-0.50
EPS:
-1.32
순현금흐름:
$-91.53M
1주 성능:
-18.67%
1개월 성능:
-13.04%
6개월 성능:
-23.35%
1년 성능:
-30.31%
1일 변동 폭
$0.66
$0.7147
1주일 범위
$0.65
$0.8601
52주 변동 폭
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.66 | 148.00M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-10 | 개시 | William Blair | Outperform |
| 2023-11-30 | 개시 | Leerink Partners | Outperform |
| 2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 4,056,573 Shares of Stock - MarketBeat
Group Gp Lp Column III Sells 343,717 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock - MarketBeat
Can Tenaya Therapeutics Inc generate free cash flowJuly 2025 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Tenaya Therapeutics Inc. stock influenced by commodity pricesWeekly Profit Recap & Capital Efficient Trading Techniques - mfd.ru
Investment Review: Is Tenaya Therapeutics Inc. stock a safe buy before earningsDividend Hike & Trade Opportunity Analysis - mfd.ru
Breakouts Watch: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan By Investing.com - Investing.com South Africa
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan - Investing.com Nigeria
Guidance Update: Is Waton Financial Limited stock a good pick for beginnersGap Down & Consistent Return Investment Signals - baoquankhu1.vn
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan - TipRanks
Tenaya Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq bid-price warning hits Tenaya Therapeutics (Nasdaq: TNYA) as equity inducement pool grows - Stock Titan
Update Report: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Is Tenaya Therapeutics Inc. part of any ETF2025 Support & Resistance & Stepwise Swing Trade Plans - mfd.ru
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway - Yahoo Finance
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise - Sahm
How Does Tenaya Therapeutics' (TNYA) Extended Cash Runway Reframe Its Cardiac Gene Therapy Ambitions? - Yahoo Finance
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 - Finviz
Tenaya Therapeutics announces orderly board leadership transition - MSN
Will Tenaya Therapeutics Inc. stock deliver shareholder valueGDP Growth & Real-Time Sentiment Analysis - bollywoodhelpline.com
9 Overlooked Growth Stocks to Buy - Insider Monkey
Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech - Insider Monkey
10 Stocks Under $1 That Will Explode - Insider Monkey
What catalysts could drive Tenaya Therapeutics Inc. stock higher2025 Trading Volume Trends & Fast Entry High Yield Tips - Улправда
Will Tenaya Therapeutics Inc. stock benefit from infrastructure spending2025 Macro Impact & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Tenaya Therapeutics announces 2026 strategic priorities - MarketScreener
Tenaya Therapeutics Outlines 2026 Milestones Following Positive Interim Results from MyPEAK™-1 and RIDGE™-1 Trials - Quiver Quantitative
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Is Tenaya Therapeutics Inc. stock supported by strong fundamentalsInflation Watch & Proven Capital Preservation Tips - ulpravda.ru
Gene therapy trials for inherited heart disease face big 2026 tests - Stock Titan
Why Tenaya Therapeutics Inc. stock could see breakout soonJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Улправда
Published on: 2026-01-09 09:18:13 - Улправда
What insider trading reveals about Tenaya Therapeutics Inc. stockEntry Point & Consistent Return Investment Signals - Улправда
Published on: 2026-01-09 03:34:26 - Bộ Nội Vụ
Why Tenaya Therapeutics Inc. stock is trending among retail tradersJuly 2025 Rallies & Free Accurate Trade Setup Notifications - Улправда
How Tenaya Therapeutics Inc. stock reacts to Fed rate cutsEarnings Beat Highlights & Affordable Portfolio Building - ulpravda.ru
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Buy Signal: Is Tenaya Therapeutics Inc stock supported by strong fundamentalsPortfolio Update Report & Daily Volume Surge Signals - moha.gov.vn
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tenaya Therapeutics Inc 주식 (TNYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| COLUMN GROUP III GP, LP | 10% Owner |
Feb 10 '26 |
Sale |
0.82 |
343,717 |
280,507 |
4,253,298 |
1.12%
0.87%
자본화:
|
볼륨(24시간):